Danaher's rebound is generating optimism, but there's still work ahead for the company to hit is 2026 growth targets.
Get this delivered to your inbox, and more info about our products and services.
The supplier of tools to drugmakers and hospitals is set up for a stronger 2026.
While the quarter was solid and 2026 is shaping up to be better than 2025, the progress has been slower than we would like.
Danaher is finally turning the corner. CNBC's Jim Cramer sees it. Wall Street does, too.
Life sciences stocks are seeing a resurgence — and that's good news for Danaher.
Danaher shares fell on the news that it was acquiring medtech player Masimo.
The reason? There was some noise around the quarterly numbers.
